Recombinant buckwheat trypsin inhibitor decreases fat accumulation via the IIS pathway in Caenorhabditis elegans.
Adipose Tissue
/ metabolism
Animals
Caenorhabditis elegans
/ drug effects
Caenorhabditis elegans Proteins
/ physiology
Caloric Restriction
Fagopyrum
/ chemistry
Forkhead Transcription Factors
/ physiology
Insulin
/ physiology
Lipolysis
/ drug effects
Receptor, Insulin
/ physiology
Recombinant Proteins
/ pharmacology
Reproduction
/ drug effects
Signal Transduction
/ drug effects
Somatomedins
/ physiology
Trypsin Inhibitors
/ pharmacology
Caenorhabditis elegans
Fat accumulation
Fat metabolism
IIS pathway
rBTI
Journal
Experimental gerontology
ISSN: 1873-6815
Titre abrégé: Exp Gerontol
Pays: England
ID NLM: 0047061
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
10
06
2019
revised:
10
09
2019
accepted:
14
10
2019
pubmed:
28
10
2019
medline:
8
9
2020
entrez:
25
10
2019
Statut:
ppublish
Résumé
Buckwheat trypsin inhibitor (BTI) is a low molecular weight polypeptide that can help to prevent metabolic diseases such as obesity, hyperglycemia and hyperlipidemia. Herein, the effects of recombinant BTI (rBTI) on fat accumulation in Caenorhabditis elegans were studied. rBTI prevented fat accumulation under normal and high glucose conditions, and led to significantly shorter body widths without affecting C. elegans feeding behavior. Results also indicate that rBTI altered fat breakdown, synthesis, and accumulation by altering the transcription, expression and activity of key enzymes in lipolysis and fat synthesis. In daf-2 and daf-16 mutants, rBTI did not prevent fat accumulation, indicating that rBTI activity relies on the insulin/insulin-like growth factor (IIS) pathway. Overall rBTI may regulate changes in lipolysis and fat synthesis by down-regulating the IIS pathway, which can affect fat accumulation. These findings support the application of rBTI in preventing obesity, hyperglycemia and hyperlipemia.
Identifiants
pubmed: 31648012
pii: S0531-5565(19)30396-1
doi: 10.1016/j.exger.2019.110753
pii:
doi:
Substances chimiques
Caenorhabditis elegans Proteins
0
Forkhead Transcription Factors
0
Insulin
0
Recombinant Proteins
0
Somatomedins
0
Trypsin Inhibitors
0
daf-16 protein, C elegans
0
DAF-2 protein, C elegans
EC 2.7.10.1
Receptor, Insulin
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110753Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.